Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury
Active Project Grant Awarded Last action
- Award ID
- R44AI183961
- Recipient
-
Ossium Health, Inc. UEI FFNHJ2RDRHW3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,330,196
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 75% complete
- Place of performance
- New Augusta, IN 46278, USA
Award details come from USAspending.gov.
Description
- Abstract
- Exposure to even moderate levels (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $579,970 | |
| Amendment | $1,000,000 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $375,113 | |
| Original award | $375,113 |
Quick answers
Who received award R44AI183961?
R44AI183961 was awarded to Ossium Health, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 14, 2024.
How much is award R44AI183961 worth?
$2,330,196 has been obligated on R44AI183961.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award